# data[].attributes.body
Restorative: Someone who can bring problem-solving skills and help with resolve if any concerns or problems arise.

# data[].attributes.body
Analytical: Someone who can provide insight into any ethical dilemmas. Someone who can bring logic and strategy to help make policy thorough.

# data[].attributes.body
Connectedness: Someone who can bring faith to the big picture. This will help with families and patients in their stages of diagnosis, denials, meeting criteria for implant, and discussing the end game.

# data[].attributes.body
Maximizer: Someone who can bring focus and excellence to the group. Brings perfection and strengthens the group between patients and specialty staff.

# data[].attributes.body
Achiever: Someone who offers a great deal of "lets-get-this-done." An overachiever at their finest.

# data[].attributes.body
Mechanical Heart animation

# data[].attributes.body
Heartmate 3 is the newest left ventricular assist device (LVAD) for those patients with advanced heart failure. The heartmate 3 is surgically implanted at the apex of the left ventricle.  The heart is still able to function normally, the heartmate 3 assists by using its centrifugal-force motor, allowing the blood to be circulated from the left ventricle to maintain homeostasis.  This allows patients with advanced heart failure to continue their normal lifestyle and provides them hope by bridging them to destination therapy.  LVADs also allow a bridge to recovery after cardiogenic shock or trauma, and can bridge them till transplant. With the Heartmate 3’s newest technology by advancing the motor, the Heartmate 3 gives a lower turbulence than the comparison of its older model the Heartmate 2. The new centrifugal pump optimizes the blood flow therefore decreasing the risk for pump thrombosis (Medgadget, 2018).

# data[].attributes.body
Activator, Input, Positive, Achiever, Responsibility

# data[].attributes.body
As the Heartmate 3 was just approved for destination therapy (DT), the increase of population in DT patients rose from 14.7% to 41.6% in the last 11 years (Birati & Jessup, 2015). Meaning more patients are candidates today and can receive this device.

There is a better survival rate one-year post-implant of 74% in comparison the its predecessor, the heartmate 2 at 68% survival rate 1-year post implant (Birati & Jessup, 2015)

Minimal surgical approach versus the prior heartmate 2 (Scmitto, Krabatsch, Damme, & Netuka, 2018).

The need for organ transplant exceeds the supply of hearts to transplant. Therefore allowing alternatives to patients.

# data[].attributes.headline
Important things to remember from one heart failure nurse specialist to another: 

# data[].attributes.subject
Important things to remember from one heart failure nurse specialist to another: 

# data[].attributes.body
1) These mechanical hearts are non-pulsatile therefore the patient will not have a palpable heartbeat.
2) Their blood pressure needs to be obtained by doppler only.
3) See your hospital policy on a code situation for mechanical hearts. CPR may not be warranted if they have an LVAD.
(Cobb, Shana BSN, RN, 2019)

# data[].attributes.body
Extreme anticoagulant, and anti-platelet therapy. If a patient has an allergy to the selected medication, they are not candidates. Current guidelines depict vitamin-K antagonists (VKA) as the anticoagulant therapy gold standard (Verheugt, 2015).

Lifelong consequences and continual learning, battery life and worrying about batteries and ability to charge them.

Risks of motor thrombus, infection at the drive-line site, internal bleeding, serial GI bleeds, and chronic nausea.

Unknown insurance coverage or overall cost to patient.

# data[].attributes.body
My opinion of using mechanical hearts is solid. With the benefits of the new motor, safety is key. From experience, thrombolytic therapy,  risks of bleeding, and thrombosis were always the biggest concerns. If the new motor can decrease risk of thrombosis, then I am all for them.

I found the family was usually exhausted after years of their loved one suffering with symptomatic heart failure. Years of exhausting medication therapy, frequent visits to their specialist, and living in a world of chronic fatigue. The benefits of living a normal life is worth it.

The education provided by the mechanical heart teams are usually phenomenal. The mechanical heart nurse, engineer and surgeon are always on call to help with questions or troubleshooting. I have seen the heartmate 2 save so many lives, the heartmate 3 is only better.

# data[].attributes.body
Abbot has been focusing the global industry of heart health based on scientific practice with the goal and spirit of maintaining heart health as its foundation of their innovations.  Abbot has been in practice for over 125 years and pride themselves in "bettering lives through better health" (Abbot, 2019).

# data[].attributes.body
August 23, 2017 Abbot medical had their HeartMate 3 approved for destination-therapy patients by the United States Food & Drug Administration (FDA) (FDA, 2017).

# data[].attributes.body
Abbot, 2019. [Image] Retrieved from: https://www.abbott.com/about-abbott/who-we-are.html

U.S. Food & Drug Administration (FDA), 2017. Retrieved from: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm581474.htm

Birati, E.Y., Jessup, M. (2015). Left ventricular assist devices in the management of heart failure. Cardiac Failure Review, 1(1). doi: 10.15420/CFR.2015.01.01.25

Heartmate 3, (2018) [Images] retrieved from: https://www.medgadget.com/wp-content/uploads/2018/10/HeartMate-3-design.jpg

Heartmate 3 (YouTube), Retrieved from: https://www.youtube.com/watch?v=T37WrT-lDhQ

Medgadget, (2018). Retrieved from: https://www.medgadget.com/2018/10/heartmate-3-heart-pump-approved-for-patients-not-eligible-for-transplant.html

Schmitto, J. D., Krabatsch T., Damme, L., Netuka, I. (2018). Less invasive heartmate 3 left v entricular assist device implantation. Journal of Thoracic Disease, 10(15), doi: http://dx.doi.org.ezproxy.uttyler.edu:2048/10.21037/jtd.2018.01.26

Verheugt, F. W. A., (2015). Anticoagulation in patients with mechanical heart valves: follow the guidelines! Netherland Heart Journal, 23(2). P. 109-110. doi:  10.1007/s12471-014-0642-9